Stock Ratings / Health Care / GENB / insiders

ZYME (47) SRPT (35) SLS (35) TRVI (39) ⌘ Pro Terminal →

Generate Biomedicines Inc. (GENB) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$15.77 +2.54% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Generate Biomedicines Inc. (GENB) carries a Roarable Rating of C- (Hold) with 61/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C- • HOLD / WATCH Cap $2.02B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERHOLD / WATCH • C-

JEV AI Jury Split (Battleground)

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D+ · Rk B-

Each axis scored 0–20

12M PRICE TARGET CONE+1.3% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for GENB)Realized 20D OHLCV Swing Band: ±12.5%

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

GENB Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (GENB)

No recent open-market Form 4 cluster sales or emergency dumps flagged on GENB. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (GENB Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

GENB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +24.86%📐 HORIZONTAL RANGE

2026-10-30O $14.86H $15.77L $14.25C $15.77VOL 1.17M

RES: $26.59SUP: $10.99SMA50: $15.00SMA200: $14.07

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

GENB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 GENB Butterfly Map → + Track GENB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on GENB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for GENB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for GENB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (GENB)

Health Care Rank #184 of 1016 ⚔️ ZYME vs GENB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (GENB vs. ZYME, SRPT, SLS, TRVI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Generate Biomedicines Inc. (GENB) ranks #184 by composite RQD confidence (61/100, grade C-) and #262 by equity capitalization ($2.02B). Within this direct 5-issuer industry benchmark cohort, GENB leads on earnings valuation at N/A trailing P/E, while SLS leads on capital efficiency and profitability with -21.8% ROIC and — gross margin. GENB currently leads its immediate peer cohort in composite quantitative strength at 61/100 (C-).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
GENB ACTIVE Generate Biomedicines Inc.	C-	61/100	—	—	—	+2.54%	$2.02B	Benchmark Subject
ZYME Zymeworks Inc.	D	47/100	—	—	-32.2%	-0.66%	$2.02B	/zyme-vs-genb →
SRPT Sarepta Therapeutics Inc.	D-	35/100	—	96.0%	-35.0%	-0.47%	$2.03B	/srpt-vs-genb →
SLS SELLAS Life Sciences Group Inc.	D-	35/100	—	—	-21.8%	-2.17%	$2.05B	/sls-vs-genb →
TRVI Trevi Therapeutics Inc.	D-	39/100	—	—	-23.7%	+2.15%	$1.97B	/trvi-vs-genb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2025–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002100782

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Generate Biomedicines Inc. (GENB) reported GAAP revenue of $0 , GAAP net income of $0, operating cash flow of $0, and free cash flow of $0 . On the balance sheet, GENB closed FY2025 with $330.2M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: N/A).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	$0	—	—	$330.2M	—

3. GENB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is GENB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Generate Biomedicines Inc. (NASDAQ: GENB) is rated C- (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 61/100 at a spot price of $15.77 (+2.54% 1D, market cap $2.02B). Pillar breakdown: Fundamental Cash Engine 10/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 9/20. Across 1016 tracked Health Care issuers, GENB ranks #184 in composite RQD confidence.

How does GENB compare to ZYME and SRPT in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), GENB carries a Roarable C- (61/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of —. By comparison, ZYME (Zymeworks Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC -32.2%, cap $2.02B) and SRPT (Sarepta Therapeutics Inc.) posts a D- grade (35/100 RQD, P/E N/A, ROIC -35.0%, cap $2.03B). Among the 5-stock peer group, GENB leads on earnings multiple (N/A) while SLS leads on capital efficiency (-21.8% ROIC).

What are the biggest fundamental strengths and SEC risk factors for GENB?

Per GENB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002100782), Generate Biomedicines Inc. generated $0 in revenue, $0 in net income, and $0 in free cash flow against $330.2M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is GENB trading relative to its 50-day, 200-day, and 52-week technical levels?

GENB last traded at $15.77 (+2.54% on volume of 1,762,250 shares), positioning the stock +5.13% above its 50-day simple moving average ($15.00) and +12.08% above its 200-day simple moving average ($14.07). Across its 52-week range of $11.00 to $22.67, GENB sits at the 40.9% percentile with a 14-day RSI of 52.8 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($13.80 to $17.74).

GENB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are GENB insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies GENB leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

Direct Sub-Reports: GENB RQD Cockpit GENB 12M Forecast GENB Earnings & Move GENB Dividends & DRIP GENB Insiders & 13F GENB Whale Options GENB Profit Sankey GENB News & Why